Westin M, Hedén P
Department of Experimental Surgery, Karolinska Institutet, Stockholm, Sweden.
Ann Plast Surg. 1988 Oct;21(4):329-34. doi: 10.1097/00000637-198810000-00006.
Calcitonin gene-related peptide (CGRP) is a bioactive neuropeptide with potent vasodilatory properties. The effect of CGRP on the no-reflow phenomenon was studied in rats. Island flaps based on the epigastric vessels were exposed to 11 hours of warm ischemia. CGRP was given as single doses before, before and after, or after the ischemic insults. Pre-ischemic treatment with CGRP increased flap survival at concentrations ranging from 10(-9) mol/L to 10(-7) mol/L. The survival rate of saline and untreated control flaps was 18.4%, calculated on the basis of tissue survival areas. The optimum survival rate after preischemic CGRP treatment was 60.3%, and after both preischemic and postischemic CGRP treatment, 66.3% (p less than 0.005 as compared with controls). Given as a single dose after the ischemic period, CGRP increased flap survival to 45.5% at 10(-7) mol/L (p less than 0.05), but no effect was found at lower concentrations. Apart from free radical scavengers, CGRP is the only agent known to delay the no-reflow phenomenon after a single postischemic dose.
降钙素基因相关肽（CGRP）是一种具有强大血管舒张特性的生物活性神经肽。在大鼠中研究了CGRP对无复流现象的影响。以腹壁血管为蒂的岛状皮瓣经历11小时的热缺血。CGRP在缺血损伤前、前后或后给予单剂量。缺血前用CGRP治疗，在浓度范围为10^(-9)mol/L至10^(-7)mol/L时可提高皮瓣存活率。根据组织存活面积计算，生理盐水和未处理对照皮瓣的存活率为18.4%。缺血前CGRP治疗后的最佳存活率为60.3%，缺血前和缺血后CGRP治疗后的存活率为66.3%（与对照组相比，p<0.005）。在缺血期后给予单剂量，CGRP在10^(-7)mol/L时可将皮瓣存活率提高至45.5%（p<0.05），但在较低浓度时未发现效果。除自由基清除剂外，CGRP是已知的唯一一种在单次缺血后剂量可延迟无复流现象的药物。
